Symcel is redefining sterility testing for ATMPs.

The calScreener+™ biocalorimeter system from Symcel represents a paradigm shift in growth-based sterility testing — reducing detection timelines to under three days. This means a >60% reduction in incubation time compared to compendial methods, while also minimizing hands-on time and providing real-time insights through continuous readouts indicating the presence or absence of contamination.

For cell and gene therapy developers, this breakthrough makes it possible to shorten vein-to-vein time, streamline workflows, and accelerate product release and time-to-market — all with the patient in focus, enabling faster access to life-saving treatments.

Headquartered at the Karolinska Institute in Stockholm, Symcel is a passionate, multidisciplinary team of innovators from 20 nationalities, including 15 PhDs, committed to transforming microbiological quality control.

Welcome to the next generation of sterility testing.